Ghazi Uddin Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ghazi Uddin Ahmed has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abedin Samadi
Kabul University of Medical Sciences Kabul Afghanistan
3 shared publications - Ahmed Asad Raza
Department of Medicine Jinnah Sindh Medical University Karachi Pakistan
3 shared publications - Anusha Tharwani
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Fnu Komal
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Fnu Muskan
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication - Haadi Uddin Ahmed
Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 15 May 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Efficacy of transcranial direct current stimulation on motor and cognitive functions in patients with multiple sclerosis: a systematic review and meta-analysis
Background: Multiple Sclerosis (MS) is a chronic neurological disorder affecting 2.8 million individuals worldwide, characterized by motor dysfunction and cognitive impairment that remain poorly addressed by pharmacological interventions alone. Transcranial Direct Current Stimulation (tDCS) has emerged as a promising non-invasive neuromodulation technique for symptom management in MS patients. Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy of tDCS in improving motor and cognitive functions in patients with MS, and to assess its safety profile. Methods: A comprehensive literature search was conducted across PubMed, Scopus, EMBASE, Wiley Online Library, and Google Scholar databases. Studies were selected based on PICOS criteria, including randomized controlled trials and quasi-experimental studies involving adults (≥ 18 years) with all types of MS receiving tDCS interventions. Methodological quality was assessed using RoB 2.0 and ROBINS-I. Meta-analyses were performed using RevMan 5.4.1 with random-effects models for outcomes with substantial heterogeneity and fixed-effects models where I 2 = 0%. Additionally, the protocol was prospectively registered with the Open Science Framework. Results: Twenty-two studies published between 2015 and 2025 were included in this review. Meta-analysis revealed that tDCS significantly improved information processing speed (SDMT: MD = 7.71, 95% CI: 1.60—13.82, p = 0.01) and functional mobility (TUG: MD = -1.03 s, 95% CI: -2.08—0.02, p = 0.05). While individual studies showed improvements in gait speed and balance, pooled analyses for these outcomes did not reach statistical significance (gait speed: MD = 0.16 m/s, 95% CI: -0.07—0.38, p = 0.18; Berg Balance Scale: MD = 1.18, 95% CI: -2.03—4.39, p = 0.47). Qualitative analysis revealed consistent improvements in manual dexterity, working memory, executive function, and complex attention. Additionally, no serious adverse events were reported across studies; mild and transient side effects (e.g., tingling, itching) were noted, and completion rates were high (98% in studies that reported them). Conclusion: This systematic review provides preliminary evidence supporting tDCS as a potentially beneficial adjunctive intervention for MS patients, particularly for cognitive processing speed enhancement based on two small studies. While individual studies reported motor improvements, pooled meta-analyses for gait speed and balance failed to demonstrate statistical significance, indicating insufficient evidence for definitive motor benefits despite positive signals in individual trials. The substantial limitation of small study numbers per meta-analysis (2—6 studies), combined with limited MS subtype-specific data in most studies, significantly constrains confidence in these findings and limits assessment of external validity across different MS populations. Larger, standardized, multi-center randomized controlled trials with adequate subgroup representation and extended follow-up periods are essential to establish clinical significance and treatment durability.
- 15 May 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessEfficacy of transcranial direct current stimulation on motor and cognitive functions in patients with multiple sclerosis: a systematic review and meta-analysis
Background: Multiple Sclerosis (MS) is a chronic neurological disorder affecting 2.8 million individuals worldwide, characterized by motor dysfunction and cognitive impairment that remain poorly addressed by pharmacological interventions alone. Transcranial Direct Current Stimulation (tDCS) has emerged as a promising non-invasive neuromodulation technique for symptom management in MS patients. Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy of tDCS in improving motor and cognitive functions in patients with MS, and to assess its safety profile. Methods: A comprehensive literature search was conducted across PubMed, Scopus, EMBASE, Wiley Online Library, and Google Scholar databases. Studies were selected based on PICOS criteria, including randomized controlled trials and quasi-experimental studies involving adults (≥ 18 years) with all types of MS receiving tDCS interventions. Methodological quality was assessed using RoB 2.0 and ROBINS-I. Meta-analyses were performed using RevMan 5.4.1 with random-effects models for outcomes with substantial heterogeneity and fixed-effects models where I 2 = 0%. Additionally, the protocol was prospectively registered with the Open Science Framework. Results: Twenty-two studies published between 2015 and 2025 were included in this review. Meta-analysis revealed that tDCS significantly improved information processing speed (SDMT: MD = 7.71, 95% CI: 1.60—13.82, p = 0.01) and functional mobility (TUG: MD = -1.03 s, 95% CI: -2.08—0.02, p = 0.05). While individual studies showed improvements in gait speed and balance, pooled analyses for these outcomes did not reach statistical significance (gait speed: MD = 0.16 m/s, 95% CI: -0.07—0.38, p = 0.18; Berg Balance Scale: MD = 1.18, 95% CI: -2.03—4.39, p = 0.47). Qualitative analysis revealed consistent improvements in manual dexterity, working memory, executive function, and complex attention. Additionally, no serious adverse events were reported across studies; mild and transient side effects (e.g., tingling, itching) were noted, and completion rates were high (98% in studies that reported them). Conclusion: This systematic review provides preliminary evidence supporting tDCS as a potentially beneficial adjunctive intervention for MS patients, particularly for cognitive processing speed enhancement based on two small studies. While individual studies reported motor improvements, pooled meta-analyses for gait speed and balance failed to demonstrate statistical significance, indicating insufficient evidence for definitive motor benefits despite positive signals in individual trials. The substantial limitation of small study numbers per meta-analysis (2—6 studies), combined with limited MS subtype-specific data in most studies, significantly constrains confidence in these findings and limits assessment of external validity across different MS populations. Larger, standardized, multi-center randomized controlled trials with adequate subgroup representation and extended follow-up periods are essential to establish clinical significance and treatment durability.
- 8 September 2025
- Published by Wolters Kluwer Health in Journal of Patient Safety
Physician Burnout and Fatigue: The Hidden Threat to Patient Safety
- 8 September 2025
- Published by Wolters Kluwer Health in Journal of Patient Safety
Physician Burnout and Fatigue: The Hidden Threat to Patient Safety
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 2125-2140
Spravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile
Background: Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) are debilitating psychiatric conditions associated with significant psychosocial and economic burdens. Conventional antidepressants, particularly SSRIs and SNRIs, often produce inadequate responses and cause sexual dysfunction, contributing to poor adherence and diminished quality of life. Aim: This review aims to evaluate the clinical efficacy, safety, and sexual side effect profile of intranasal esketamine (Spravato) in the treatment of MDD and TRD, highlighting its potential advantages over traditional antidepressants. Methods: A narrative literature review was conducted using PubMed, ScienceDirect, Cochrane Library, and Google Scholar. Clinical trials, meta-analyses, and systematic reviews published between 2000 and 2025 were included. Keywords used included “Spravato”, “esketamine”, “treatment-resistant depression”, and “sexual dysfunction.”. Results: Clinical trials such as TRANSFORM-2, SUSTAIN-1, and ASPIRE I/II demonstrate that esketamine provides rapid antidepressant effects—often within hours—and improves remission and response rates in TRD. Its NMDA receptor antagonism promotes synaptogenesis and neuroplasticity, distinguishing it mechanistically from monoaminergic antidepressants. Compared to SSRIs/SNRIs, Spravato exhibits a significantly lower incidence of treatment-emergent sexual dysfunction (TESD), with less than 1% of patients reporting such side effects. However, the drug’s use is constrained by dissociative symptoms, blood pressure changes, and its mandatory in-clinic administration due to REMS (Risk Evaluation and Mitigation Strategy) requirements. Conclusion: Spravato (esketamine) is an innovative and effective treatment option for TRD and severe MDD, offering rapid symptom relief and a favorable sexual side effect profile. Despite logistical and financial limitations, it represents a critical advancement in personalized psychiatry, especially for patients unresponsive to conventional therapy.
- 1 September 2025
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 21, 2125-2140
Open AccessSpravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile
Background: Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) are debilitating psychiatric conditions associated with significant psychosocial and economic burdens. Conventional antidepressants, particularly SSRIs and SNRIs, often produce inadequate responses and cause sexual dysfunction, contributing to poor adherence and diminished quality of life. Aim: This review aims to evaluate the clinical efficacy, safety, and sexual side effect profile of intranasal esketamine (Spravato) in the treatment of MDD and TRD, highlighting its potential advantages over traditional antidepressants. Methods: A narrative literature review was conducted using PubMed, ScienceDirect, Cochrane Library, and Google Scholar. Clinical trials, meta-analyses, and systematic reviews published between 2000 and 2025 were included. Keywords used included “Spravato”, “esketamine”, “treatment-resistant depression”, and “sexual dysfunction.”. Results: Clinical trials such as TRANSFORM-2, SUSTAIN-1, and ASPIRE I/II demonstrate that esketamine provides rapid antidepressant effects—often within hours—and improves remission and response rates in TRD. Its NMDA receptor antagonism promotes synaptogenesis and neuroplasticity, distinguishing it mechanistically from monoaminergic antidepressants. Compared to SSRIs/SNRIs, Spravato exhibits a significantly lower incidence of treatment-emergent sexual dysfunction (TESD), with less than 1% of patients reporting such side effects. However, the drug’s use is constrained by dissociative symptoms, blood pressure changes, and its mandatory in-clinic administration due to REMS (Risk Evaluation and Mitigation Strategy) requirements. Conclusion: Spravato (esketamine) is an innovative and effective treatment option for TRD and severe MDD, offering rapid symptom relief and a favorable sexual side effect profile. Despite logistical and financial limitations, it represents a critical advancement in personalized psychiatry, especially for patients unresponsive to conventional therapy.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2025 (1) , 8517387
Othello Syndrome Induced by Dopamine Agonists in Parkinson’s Disease: A Case Report
Background: Othello syndrome (OS) is a rare psychiatric disorder characterized by delusional jealousy and unfounded suspicions of infidelity. It has been associated with neurological diseases such as Parkinson’s disease (PD), particularly in patients receiving dopamine agonists (DAs). Case Presentation: A 69‐year‐old man with a longstanding diagnosis of PD developed OS after transitioning from levodopa/carbidopa to ropinirole due to intolerance. Six months after initiating ropinirole, the patient began experiencing intense, delusional beliefs regarding his wife’s fidelity, despite no cognitive decline or psychiatric history. The delusional symptoms significantly strained his marital relationship. Clinical Findings and Diagnostic Assessment: Neurological examination remained consistent with PD, and no structural brain abnormalities were observed on magnetic resonance imaging (MRI). The temporal association between ropinirole use and symptom onset led to the diagnosis of ropinirole‐induced OS. Ropinirole was gradually discontinued over 4 weeks, and quetiapine was introduced. The patient showed substantial improvement in psychiatric symptoms with resolution of delusional beliefs and restoration of spousal rapport. Conclusion: This case highlights the potential for DAs, including ropinirole, to induce OS in PD patients. Clinicians should remain vigilant for psychiatric side effects during PD treatment and consider timely intervention, including medication adjustment and antipsychotic therapy, to prevent severe psychosocial consequences.
- 1 January 2025
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2025 (1) , 8517387
Open AccessOthello Syndrome Induced by Dopamine Agonists in Parkinson’s Disease: A Case Report
Background: Othello syndrome (OS) is a rare psychiatric disorder characterized by delusional jealousy and unfounded suspicions of infidelity. It has been associated with neurological diseases such as Parkinson’s disease (PD), particularly in patients receiving dopamine agonists (DAs). Case Presentation: A 69‐year‐old man with a longstanding diagnosis of PD developed OS after transitioning from levodopa/carbidopa to ropinirole due to intolerance. Six months after initiating ropinirole, the patient began experiencing intense, delusional beliefs regarding his wife’s fidelity, despite no cognitive decline or psychiatric history. The delusional symptoms significantly strained his marital relationship. Clinical Findings and Diagnostic Assessment: Neurological examination remained consistent with PD, and no structural brain abnormalities were observed on magnetic resonance imaging (MRI). The temporal association between ropinirole use and symptom onset led to the diagnosis of ropinirole‐induced OS. Ropinirole was gradually discontinued over 4 weeks, and quetiapine was introduced. The patient showed substantial improvement in psychiatric symptoms with resolution of delusional beliefs and restoration of spousal rapport. Conclusion: This case highlights the potential for DAs, including ropinirole, to induce OS in PD patients. Clinicians should remain vigilant for psychiatric side effects during PD treatment and consider timely intervention, including medication adjustment and antipsychotic therapy, to prevent severe psychosocial consequences.